Document Detail

Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
MedLine Citation:
PMID:  12362237     Owner:  NLM     Status:  MEDLINE    
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a relatively recently described glycoprotein (MM 55 KDa) that can be converted into its active form by the thrombin/thrombomodulin complex and potentially inhibits fibrinolysis. Since it represents a link between coagulation and fibrinolysis, TAFI can be expected to play a part in various clinical conditions associated with a thrombotic tendency. Preeclampsia (PE) and intrauterine fetal growth retardation (IUFGR) are fairly common complications of pregnancy that are characterized by hemostatic abnormalities. TAFI antigen and its influence on hemostasis was investigated in 46 women with PE and/or IUFGR and in 16 normal pregnancies. We found a significant decrease of TAFI antigen in the patient group. Using the recently described method Overall Hemostatic Potential (OHP) in plasma we measured clot lysis time (CLT) and overall fibrinolytic potential (OFP). We found that CLT is prolonged and OFP decreased in patients with PE and/or IUFGR. Since OFP did not increase after addition of the specific inhibitor of TAFI (potato tuber carboxypeptidase inhibitor), it seems that TAFI does not contribute to the impairment of fibrinolysis in these patients. Since serum albumin was decreased together with presence of proteinuria and aminotransferases were increased in the patients, it seems that one explanation for the decrease in TAFI could be reduced hepatic synthesis and an increased loss in urine. It an be speculated that this mechanism can prevent more serious thrombotic complications in patients with PE and/or IUFGR.
J P Antovic; R Rafik Hamad; A Antovic; M Blombäck; K Bremme
Related Documents :
9833857 - Predictors of a viral response and subsequent virological treatment failure in patients...
2945517 - Thrombocytopenia following peritonitis in surgical patients. a prospective study.
1428207 - Nafamostat as anti-coagulant for membrane plasmapheresis in high bleeding risk patients.
9040747 - Torsional eye movements in patients with skew deviation and spasmodic torticollis: resp...
24953587 - Multidrug-resistant tubercular liver abscess in b-thalassemia.
6343447 - Measurement of functional residual capacity during mechanical ventilation. comparison o...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  88     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2002 Oct 
Date Detail:
Created Date:  2002-10-03     Completed Date:  2003-07-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  644-7     Citation Subset:  IM    
Coagulation Research, Department of Surgical Sciences, Karolinska Hospital, Karolinska Insitute, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carboxypeptidase U / blood*,  physiology
Case-Control Studies
Fetal Growth Retardation / blood*,  physiopathology
Fibrinolysis / physiology*
Pre-Eclampsia / blood*,  physiopathology
Serum Albumin / analysis
Transaminases / blood
Reg. No./Substance:
0/Serum Albumin; EC 2.6.1.-/Transaminases; EC U

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The endotoxin-induced plasminogen activator inhibitor-1 increase in rabbits is not tumor necrosis fa...
Next Document:  Physical and functional interaction between cell-surface calreticulin and the collagen receptors int...